β-arrestin 2 regulates Aβ generation and γ-secretase activity in Alzheimer's disease

被引:146
作者
Thathiah, Amantha [1 ,2 ,3 ]
Horre, Katrien [1 ,2 ,3 ]
Snellinx, An [1 ,2 ,3 ]
Vandewyer, Elke [1 ,2 ,3 ]
Huang, Yunhong [1 ,2 ,3 ]
Ciesielska, Marta [1 ,2 ,3 ]
De Kloe, Gerdien [1 ,4 ]
Munck, Sebastian [1 ,2 ,3 ]
De Strooper, Bart [1 ,2 ,3 ]
机构
[1] VIB, Ctr Biol Dis, Louvain, Belgium
[2] Univ Leuven KU Leuven, Ctr Human Genet, Louvain, Belgium
[3] Univ Leuven KU Leuven, LIND, Louvain, Belgium
[4] Janssen Pharmaceut, Dept Neurosci, Johnson & Johnson Pharmaceut Res & Dev, B-2340 Beerse, Belgium
关键词
PROTEIN-COUPLED RECEPTORS; LIPID RAFTS; ACTIVATION; BETA-ARRESTIN-2; PRESENILIN-1; REVEALS; DESENSITIZATION; THERAPEUTICS; CONTRIBUTES; DEFICIENCY;
D O I
10.1038/nm.3023
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
beta-arrestins are associated with numerous aspects of G protein-coupled receptor (GPCR) signaling and regulation and accordingly influence diverse physiological and pathophysiological processes. Here we report that beta-arrestin 2 expression is elevated in two independent cohorts of individuals with Alzheimer's disease. Overexpression of beta-arrestin 2 leads to an increase in amyloid-beta (A beta) peptide generation, whereas genetic silencing of Arrb2 (encoding beta-arrestin 2) reduces generation of A beta in cell cultures and in Arrb2(-/-) mice. Moreover, in a transgenic mouse model of Alzheimer's disease, genetic deletion of Arrb2 leads to a reduction in the production of A beta(40) and A beta(42). Two GPCRs implicated previously in Alzheimer's disease (GPR3 and the beta(2)-adrenergic receptor) mediate their effects on A beta generation through interaction with beta-arrestin 2. beta-arrestin 2 physically associates with the Aph-1a subunit of the gamma-secretase complex and redistributes the complex toward detergent-resistant membranes, increasing the catalytic activity of the complex. Collectively, these studies identify beta-arrestin 2 as a new therapeutic target for reducing amyloid pathology and GPCR dysfunction in Alzheimer's disease.
引用
收藏
页码:43 / 49
页数:7
相关论文
共 50 条
  • [41] γ-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS)
    Schultz, Stephanie A.
    Liu, Lei
    Schultz, Aaron P.
    Fitzpatrick, Colleen
    Levin, Raina
    Bellier, Jean-Pierre
    Shirzadi, Zahra
    Joseph-Mathurin, Nelly
    Chen, Charles
    Benzinger, Tammie L. S.
    Day, Gregory S.
    Farlow, Martin R.
    Gordon, Brian A.
    Hassenstab, Jason J.
    Jack Jr, Clifford R.
    Jucker, Mathias
    Karch, Celeste M.
    Lee, Jae-Hong
    Levin, Johannes
    Perrin, Richard J.
    Schofield, Peter R.
    Xiong, Chengjie
    Johnson, Keith A.
    Mcdade, Eric
    Bateman, Randall J.
    Sperling, Reisa A.
    Selkoe, Dennis J.
    Chhatwal, Jasmeer P.
    LANCET NEUROLOGY, 2024, 23 (09) : 913 - 924
  • [42] Donepezil, a drug for Alzheimer's disease, promotes oligodendrocyte generation and remyelination
    Cui, Xue
    Guo, Yu-e
    Fang, Jia-hui
    Shi, Chang-jie
    Suo, Na
    Zhang, Ru
    Xie, Xin
    ACTA PHARMACOLOGICA SINICA, 2019, 40 (11) : 1386 - 1393
  • [43] Cholesterol Regulates μ-Opioid Receptor-Induced β-Arrestin 2 Translocation to Membrane Lipid Rafts
    Qiu, Yu
    Wang, Yan
    Law, Ping-Yee
    Chen, Hong-Zhuan
    Loh, Horace H.
    MOLECULAR PHARMACOLOGY, 2011, 80 (01) : 210 - 218
  • [44] Friend, Foe or Both? Immune Activity in Alzheimer's Disease
    Frost, Georgia R.
    Jonas, Lauren A.
    Li, Yue-Ming
    FRONTIERS IN AGING NEUROSCIENCE, 2019, 11
  • [45] The product of the γ-secretase processing of ephrinB2 regulates VE-cadherin complexes and angiogenesis
    Warren, Noel A.
    Voloudakis, Georgios
    Yoon, Yonejung
    Robakis, Nikolaos K.
    Georgakopoulos, Anastasios
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2018, 75 (15) : 2813 - 2826
  • [46] Inhibition of Cholesterol Biosynthesis Reduces γ-Secretase Activity and Amyloid-β Generation
    Kim, Yoonhee
    Kim, Chaeyoung
    Jang, Hye Young
    Mook-Jung, Inhee
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 51 (04) : 1057 - 1067
  • [47] NOX2 in Alzheimer's and Parkinson's disease
    Dustin, Christopher M.
    Shiva, Sruti S.
    Vazquez, Alberto
    Saeed, Anum
    Pascoal, Tharick
    Cifuentes-Pagano, Eugenia
    Pagano, Patrick J.
    REDOX BIOLOGY, 2024, 78
  • [48] CRISPR Transcriptional Activation Analysis Unmasks an Occult γ-Secretase Processivity Defect in Familial Alzheimer's Disease Skin Fibroblasts
    Inoue, Keiichi
    Oliveira, Luis M. A.
    Abeliovich, Asa
    CELL REPORTS, 2017, 21 (07): : 1727 - 1736
  • [49] Pharmacological characterization of the novel γ-secretase modulator AS2715348, a potential therapy for Alzheimer's disease, in rodents and nonhuman primates
    Mitani, Yasuyuki
    Akashiba, Hiroki
    Saita, Kyoko
    Yarimizu, Junko
    Uchino, Hiroshi
    Okabe, Mayuko
    Asai, Makoto
    Yamasaki, Shingo
    Nozawa, Takashi
    Ishikawa, Noritoshi
    Shitaka, Yoshitsugu
    Ni, Keni
    Matsuoka, Nobuya
    NEUROPHARMACOLOGY, 2014, 79 : 412 - 419
  • [50] mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies
    Caccamo, Antonella
    Magri, Andrea
    Medina, David X.
    Wisely, Elena V.
    Lopez-Aranda, Manuel F.
    Silva, Alcino J.
    Oddo, Salvatore
    AGING CELL, 2013, 12 (03) : 370 - 380